133 related articles for article (PubMed ID: 26671737)
1. Young investigator challenge: Cadherin-17 and SATB2 in cytology specimens: Do these new immunostains help in differentiating metastatic colorectal adenocarcinoma from adenocarcinomas of other origins?
Brandler TC; Jelloul FZ; Soto D; Das K; Rosen L; Bhuiya TA
Cancer Cytopathol; 2015 Dec; 123(12):706-13. PubMed ID: 26671737
[TBL] [Abstract][Full Text] [Related]
2. Combination of cadherin-17 and SATB homeobox 2 serves as potential optimal makers for the differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal adenocarcinoma.
Bian T; Zhao J; Feng J; Zhang Q; Qian L; Liu J; Jiang D; Liu Y; Zhang J
Oncotarget; 2017 Sep; 8(38):63442-63452. PubMed ID: 28969003
[TBL] [Abstract][Full Text] [Related]
3. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
4. Cadherin-17 and SATB2 are sensitive and specific immunomarkers for medullary carcinoma of the large intestine.
Lin F; Shi J; Zhu S; Chen Z; Li A; Chen T; Wang HL; Liu H
Arch Pathol Lab Med; 2014 Aug; 138(8):1015-26. PubMed ID: 24437456
[TBL] [Abstract][Full Text] [Related]
5. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
Dabir PD; Svanholm H; Christiansen JJ
APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
[TBL] [Abstract][Full Text] [Related]
6. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.
Meagher NS; Wang L; Rambau PF; Intermaggio MP; Huntsman DG; Wilkens LR; El-Bahrawy MA; Ness RB; Odunsi K; Steed H; Herpel E; Anglesio MS; Zhang B; Lambie N; Swerdlow AJ; Lubiński J; Vierkant RA; Goode EL; Menon U; Toloczko-Grabarek A; Oszurek O; Bilic S; Talhouk A; García-Closas M; Wang Q; Tan A; Farrell R; Kennedy CJ; Jimenez-Linan M; Sundfeldt K; Etter JL; Menkiszak J; Goodman MT; Klonowski P; Leung Y; Winham SJ; Moysich KB; Behrens S; Kluz T; Edwards RP; Gronwald J; Modugno F; Hernandez BY; Chow C; Kelemen LE; Keeney GL; Carney ME; Natanzon Y; Robertson G; Sharma R; Gayther SA; Alsop J; Luk H; Karpinskyj C; Campbell I; Sinn P; Gentry-Maharaj A; Coulson P; Chang-Claude J; Shah M; Widschwendter M; Tang K; Schoemaker MJ; Koziak JM; Cook LS; Brenton JD; Daley F; Kristjansdottir B; Mateoiu C; Larson MC; Harnett PR; Jung A; deFazio A; Gorringe KL; Pharoah PDP; Minoo P; Stewart C; Bathe OF; Gui X; Cohen P; Ramus SJ; Köbel M
Mod Pathol; 2019 Dec; 32(12):1834-1846. PubMed ID: 31239549
[TBL] [Abstract][Full Text] [Related]
7. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
[TBL] [Abstract][Full Text] [Related]
8. SATB2 Versus CDX2: A Battle Royale for Diagnostic Supremacy in Mucinous Tumors.
Brettfeld SM; Ramos BD; Berry RS; Martin DR; Hanson JA
Arch Pathol Lab Med; 2019 Sep; 143(9):1119-1125. PubMed ID: 30838879
[TBL] [Abstract][Full Text] [Related]
9. The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma.
Skalova A; Sar A; Laco J; Metelkova A; Miesbauerova M; Steiner P; Švajdler M; Michal M
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):140-146. PubMed ID: 27258560
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic value of SATB2, CK7 and CK20 in colorectal cancer].
Lyn J; Wang Y; Wang F; Shen M; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):578-81. PubMed ID: 26705182
[TBL] [Abstract][Full Text] [Related]
11. Role of conventional immunomarkers, HNF4-α and SATB2, in the differential diagnosis of pulmonary and colorectal adenocarcinomas.
Kriegsmann M; Harms A; Longuespée R; Muley T; Winter H; Kriegsmann K; Kazdal D; Goeppert B; Pathil A; Warth A
Histopathology; 2018 May; 72(6):997-1006. PubMed ID: 29243296
[TBL] [Abstract][Full Text] [Related]
12. The role of SATB2 as a diagnostic marker for tumors of colorectal origin: Results of a pathology-based clinical prospective study.
Dragomir A; de Wit M; Johansson C; Uhlen M; Pontén F
Am J Clin Pathol; 2014 May; 141(5):630-8. PubMed ID: 24713733
[TBL] [Abstract][Full Text] [Related]
13. SATB2 is a novel marker of osteoblastic differentiation and colorectal adenocarcinoma.
Ordóñez NG
Adv Anat Pathol; 2014 Jan; 21(1):63-7. PubMed ID: 24316906
[TBL] [Abstract][Full Text] [Related]
14. SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas.
Zhang YJ; Chen JW; He XS; Zhang HZ; Ling YH; Wen JH; Deng WH; Li P; Yun JP; Xie D; Cai MY
EBioMedicine; 2018 Feb; 28():62-69. PubMed ID: 29396302
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin.
Yang C; Sun L; Zhang L; Zhou L; Zhao M; Peng Y; Niu D; Li Z; Huang X; Kang Q; Jia L; Lai J; Cao D
Am J Surg Pathol; 2018 Feb; 42(2):160-171. PubMed ID: 28914716
[TBL] [Abstract][Full Text] [Related]
16. Dual Immunostain With SATB2 and CK20 Differentiates Appendiceal Mucinous Neoplasms From Ovarian Mucinous Neoplasms.
Li Z; Roth R; Rock JB; Lehman A; Marsh WL; Suarez A; Frankel WL
Am J Clin Pathol; 2017 May; 147(5):484-491. PubMed ID: 28340228
[TBL] [Abstract][Full Text] [Related]
17. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic.
Perez Montiel D; Arispe Angulo K; Cantú-de León D; Bornstein Quevedo L; Chanona Vilchis J; Herrera Montalvo L
Ann Diagn Pathol; 2015 Aug; 19(4):249-52. PubMed ID: 26059401
[TBL] [Abstract][Full Text] [Related]
18. Colitis-associated colorectal adenocarcinomas are frequently associated with non-intestinal mucin profiles and loss of SATB2 expression.
Iwaya M; Ota H; Tateishi Y; Nakajima T; Riddell R; Conner JR
Mod Pathol; 2019 Jun; 32(6):884-892. PubMed ID: 30710095
[TBL] [Abstract][Full Text] [Related]
19. Value of SATB2 immunostaining in the distinction between small intestinal and colorectal adenocarcinomas.
Kim CJ; Baruch-Oren T; Lin F; Fan XS; Yang XJ; Wang HL
J Clin Pathol; 2016 Dec; 69(12):1046-1050. PubMed ID: 27169755
[TBL] [Abstract][Full Text] [Related]
20. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas.
Magnusson K; de Wit M; Brennan DJ; Johnson LB; McGee SF; Lundberg E; Naicker K; Klinger R; Kampf C; Asplund A; Wester K; Gry M; Bjartell A; Gallagher WM; Rexhepaj E; Kilpinen S; Kallioniemi OP; Belt E; Goos J; Meijer G; Birgisson H; Glimelius B; Borrebaeck CA; Navani S; Uhlén M; O'Connor DP; Jirström K; Pontén F
Am J Surg Pathol; 2011 Jul; 35(7):937-48. PubMed ID: 21677534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
